Abstract
The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed the link between gut lumen antigenic/toxic substances and systemic and liver inflammation in NAFLD and obesity, metabolic syndrome. Recent evidence from the literature show how IP can be modulated by several non-pharmacological and pharmacological agents and be the target for future preventive and curative treatment of NAFLD and NASH.
In this review we describe the concept of IP, its ultrastructural basis, its role in the NALFD pathophysiology and emerging evidence on non-pharmacological and pharmacological agents able to favourably modulate it.
Keywords: Intestinal permeability, zonulin-1, claudin, nafld, nash, lipopolysaccharide.
Graphical Abstract
Reviews on Recent Clinical Trials
Title:Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Volume: 9 Issue: 3
Author(s): Scarpellini E., Lupo M., Iegri C., Gasbarrini A., De Santis A. and Tack J.
Affiliation:
Keywords: Intestinal permeability, zonulin-1, claudin, nafld, nash, lipopolysaccharide.
Abstract: The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed the link between gut lumen antigenic/toxic substances and systemic and liver inflammation in NAFLD and obesity, metabolic syndrome. Recent evidence from the literature show how IP can be modulated by several non-pharmacological and pharmacological agents and be the target for future preventive and curative treatment of NAFLD and NASH.
In this review we describe the concept of IP, its ultrastructural basis, its role in the NALFD pathophysiology and emerging evidence on non-pharmacological and pharmacological agents able to favourably modulate it.
Export Options
About this article
Cite this article as:
E. Scarpellini, M. Lupo, C. Iegri, A. Gasbarrini, Santis A. De and J. Tack, Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis, Reviews on Recent Clinical Trials 2014; 9 (3) . https://dx.doi.org/10.2174/1574887109666141216104334
DOI https://dx.doi.org/10.2174/1574887109666141216104334 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Structure – Based to Knowledge – Based Drug Design Through X-Ray Protein Crystallography: Sketching Glycogen Phosphorylase Binding Sites
Current Medicinal Chemistry Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Lipid Management and Peripheral Arterial Disease
Current Drug Targets Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research Editorial (Thematic Issue: The (Same Old) Problem of Uncontrolled Hypertension)
Current Hypertension Reviews Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions
Current Drug Delivery Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Calcium Channel Blockers in the Management of Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Sildenafil and Cardioprotection
Current Pharmaceutical Design Prediabetic Dysglycemia: Call for Action
Current Diabetes Reviews Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments
Current Pharmaceutical Design